Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Toni Choueiri, MD Profile picture
@DrChoueiri
Dec 29, 2022 • 11 tweets • 21 min read • Read on X
Scrolly
It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2022:

Some negative, some positive, but we learned from all!

Feel free to add more & retweet & tag anyone involved

This is not an exhaustive list!

@OncoAlert @DanaFarber

#OnwardFor2023 Image
1/ #ARASENS phase 3 trial shows ⬆️OS with darolutamide in combination with docetaxel and ADT in #mHSPC (vs docetaxel + ADT alone) with similar AE profile, leading to @US_FDA approval.
#MatthewSmith @BertrandTOMBAL @MGHMedicine @NEJM
nejm.org/doi/full/10.10… ImageImageImage
2/ In #PCa patients with detectable PSA after prostatectomy, lymph node RT + ADT+ PBRT⬆️freedom from progression compared to ADT+ PBRT and PBRT alone according to #SPPORT trial.
@_APollack @DrHowardSandler @TheLancet
thelancet.com/journals/lance… ImageImage
3/ Another @US_FDA approved triplet therapy in de novo #mCSPC: abiraterone (+ ADT + docetaxel) improves OS and radiographic PFS compared to SOC±RT in the #PEACE-1 trial with modest⬆️toxicity (mainly HTN).
#Fizazi @AlbertoBossial @GustaveRoussy @TheLancet
thelancet.com/journals/lance… ImageImage
4/ In 2 #STAMPEDE RCTs: Abiraterone (±enzalutamide) combined with ADT in high risk M0 #PCa⬆️metastasis-free survival, OS, PFS, DSS. Unclear benefit of adding enzalutamide with⬆️toxicity.
@AttardLab @Prof_Nick_James @mattsydes @TheLancet @Silke_Gillessen
thelancet.com/journals/lance… ImageImageImage
5/ IL-15 superagonist NAI can induce persistent CR in 71% of BCG-unresponsive #NMIBC with #CIS + 89% avoided cystectomy and 100% DSS at 2 years.
@UroCancerMD @UclaUrology @DrPatSoonShiong @NEJMEvidence
evidence.nejm.org/doi/full/10.10… ImageImageImage
6/ In the GETUG-AFU V05 #VESPER trial, neoadjuvant dd-MVAC for M0 #MIBC ⬆️3-year PFS compared to Gem/Cis.
@GETUG_Unicancer @JCO_ASCO
ascopubs.org/doi/full/10.12… ImageImageImage
7/ Promising data from 1L enfortumab vedotin + pembrolizumab in cis-ineligible, metastatic #urothelial cancer (EV-103): ORR 73.3%, CRR 15.6% with good tolerability. Median DOR &OS exceeding 2 years. 👀on phase 3 trial.

@DrChrisHoimes @DrRosenbergMSK @JCO_ASCO @OncologyTimes ImageImage
8/ Data from the #IMmotion010 trial: adjuvant atezolizumab unfortunately did not meet its primary endpoint of improved DFS in #RCC at high risk of recurrence after nephrectomy.
@montypal @UzzoRob #AxelBex @AlbigesL @brian_rini @crisuarez08
thelancet.com/journals/lance… ImageImageImage
9/ Promising efficacy of cabozantinib/nivolumab in the treatment of papillary, unclassified and translocation-associated #RCC with a 47.5% ORR (median PFS 12.5 mos and OS 28 mos). Limited response in chromophobe RCC.

@ChungHanLee3 @motzermd @JCO_ASCO
ascopubs.org/doi/full/10.12… ImageImage
10/ In the phase 2 #SAKK 01/10 trial, single-dose carboplatin followed by involved-node RT in stage II #seminoma showed a favorable efficacy and toxicity profile with 93.7% PFS at 3 years.
@Alex_Papachris @SAKK_ch @TheLancetOncol ImageImageImage

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Toni Choueiri, MD

Toni Choueiri, MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrChoueiri

Toni Choueiri, MD Profile picture
Dec 26, 2023
And now, onto the Top 10 Translational GU Papers of 20-23. Again, not an exhaustive list, with some our @DanaFarber @DanaFarber_GU being involved in.

Let us start! Image
1/#RCC histological subtypes display diverse epigenetic configurations. Allelic imbalances play a role in modifying TF binding sites, especially through candidate SNPs.

Potential targets for future investigations and therapeutic strategies?

@AminNassarMD @sarahaboualaiwi @SylvanBacaLab #FreedmanLab

nature.com/articles/s4146…Image
Image
Image
2/ Unlocking metastatic secrets: 🧬A novel #RCC model created with CRISPR-Cas9 editing reveals 9p21 disruption’s role, recurrent patterns driving progression, and #INF signaling’s

@perelli_luigi @LabGenovese @NatureCancer
nature.com/articles/s4301…

Image
Image
Read 11 tweets
Toni Choueiri, MD Profile picture
Dec 24, 2023
It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2023: Some negative, some positive, but we learned from all!

Feel free to add more & retweet & tag

This is not an exhaustive list!

@OncoAlert @danafarber @DanaFarber_GU

#OnwardFor2024 Image
1/#COSMIC-313 phase 3 trial shows ⬆️PFS with Cabozantinib plus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic #RCC presented @myESMO #ESMO22

@motzermd @NEJM @tompowles1 @AlbigesL @DrDanielHeng @FabioSchutz78 @BurottoMauricio



COI: trial PInejm.org/doi/full/10.10…Image
2/In HRR-def #mCRPC: adding talazoparib to enza as 1L improved rPFS(HR=0.45), #PSA-progression, time to chemo, RR, could ⬆️OS (HR=0.69, immature) from Ph 3 #TALAPRO-2 trial. Presented #GU23 @ASCO

@neerajaiims @NatureMedicine #Fizazi @AzadOncology

nature.com/articles/s4159…


Image
Image
Image
Read 11 tweets
Toni Choueiri, MD Profile picture
May 27, 2022
Now that #ASCO22 abstracts are released, more insights into Top 10 #GUOnc abstracts (still many LBAs):

@DanaFarber_GU @OncoAlert @ASCO @ASCOPost

1/LBA| Chris Ryan @OHSUKnight=>The long awaited EVEREST study with adjuvant everolimus in RCC: stay tuned!
2/Interesting relationship between DepOR and clinical outcomes in CM-9ER! Greater proportions of pts receiving Nivo+Cabo had deeper responses vs SUN. This translated into better PFS/OS

Dr. Cristina Súarez @vallhebron Image
3/Better HEQOL baseline scores were associated with significantly reduced death on Checkmate-214. Pts with improved/stable 6mo-HRQoL had a 52% reduction in risk of death compared to pts who had worsened.
@CellaDavid @MSSatNU Image
Read 10 tweets
Toni Choueiri, MD Profile picture
Dec 28, 2021
It is this time of the year again: TOP 20 GU Oncology clinical trials published in 2021:

Some negative, some positive, some led to @FDAOncology approval; we learned from all!

Feel free to add & retweet & tag anyone involved

This is not an exhaustive list

@OncoAlert
1/ (177Lu)–PSMA-617 showing improved PFS and OS in pre-treated mCRPC patients vs. SOC, in addition to a favorable safety profile @sartor_oliver @morr316 @NEJM
nejm.org/doi/full/10.10…
2/ MRI with targeted & standard biopsy in men with MRI suggestive of prostate cancer (PC) was noninferior to standard biopsy for detecting clinically significant PC &resulted in less detection of clinically insignificant cancer @NEJM @TobiasNordstrom
nejm.org/doi/full/10.10…
Read 22 tweets
Toni Choueiri, MD Profile picture
Aug 18, 2021
1/ On the heels of @ASCO #ASCO21 plenary, we are happy to share the results of KEYNOTE-564 trial of adjuvant pembrolizumab in mRCC just published in @NEJM ! A step towards better outcomes for all our patients with kidney cancer!
nejm.org/doi/full/10.10…
@OncoAlert @tompowles1
2/ Following nephrectomy for kidney cancer, a significant percentage of patients will experience disease recurrence, most of them with distant metastases, highlighting the need for effective adjuvant therapies.
3/ Despite many decades of research and clinical investigations, there are currently no globally approved adjuvant regimens for the management of #kidneycancer
Read 16 tweets
Toni Choueiri, MD Profile picture
Apr 22, 2021
Just out @NatureMedicine: Inhibition of HIF-2 alpha in RCC with belzutfian (MK-6482) - phase 1 trial and biomarker analysis- 1st study to report on the 2nd gen. HIF-2 inhibitors in pts with metastatic ccRCC!! @OncoAlert

A THREAD!

nature.com/articles/s4159…
1/The HIF2 axis biology is fascinating culminating in a 2019 @nobel prize, including our own @DanaFarber @kaelin_lab
2/In this study: 95 patients were enrolled (dose-escalation cohort: n=43 and dose-expansion cohort: n=52). Among these, 55 had advanced ccRCC, with a median age of 62 years, a median of 3 previous systemic therapies, and 76% (n=42) with intermediate/poor @IMDConline risk groups.
Read 16 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(